Bortezomib Active Not Recruiting Phase 2 Trials for Neurologic toxicity / Therapy-Related Toxicity / Malignant Lymphomas Treatment

IndicationsStatusPurposePhase
Active Not RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01415752Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma